14-Nov-2024 3:05 PM CST - Business Wire Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastoge
14-Nov-2024 3:05 PM CST - Business Wire Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastoge
